FDA Investigation Raises Broader Questions About 510(k) Statute
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent reexamination of a contentious 510(k)-clearance revealed not only serious deviations from agency protocol in that instance, but also systemic problems with the 510(k) process itself, FDA said last week
You may also be interested in...
Internal FDA Menaflex Investigation Finds Serious Process Deviations
An internal evaluation of FDA's handling of the controversial 510(k) clearance of a knee implant unearthed serious shortcomings in the integrity of the agency's review process, FDA said Sept. 24
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.